Option chain shows key data for Nutex Health's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Nutex Health.

Nutex Health (NASDAQ:NUTX) Stock, Option Chain

Nutex Health

Nutex Health Inc is healthcare services and operations company with 20 hospital facilities in eight states (hospital division), and a primary care-centric, risk-bearing population health management division. The hospital division implements and operates healthcare models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management division owns and operates provider networks such as independent physician associations (IPAs) and offers a cloud-based proprietary technology platform to IPAs that aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers.

xr:d:DAFlIpbTT1A:2,j:4116682735297072717,t:23060710

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

BWAQ

CTGO

CVGW

HOTH

HOVR

IDAI

KITT

KXIN

MITQ

Nuveen Insured California Premium Fund Ii

NUTX

PIXY

PROK

TCTM

TROO

YEXT

Why Calavo Growers Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket

Penny Stocks

Small Cap

Intraday Update

ACOR

ADIL

ASTI

BNRG

BPTS

BSGM

CISS

DCGO

DECK

DOGZ

DXYZ

EZGO

GRRR

ICCT

IFBD

IMRN

JAGX

MGAM

MRIN

MRNO

NEOV

NOVA

OPEN

PRFX

RETO

RVMD

TSLA

VERB

VIAO

VINO

Shares of  Ascent Solar Technologies, Inc. (NASDAQ: ASTI) fell sharply during Wednesday’s session after the company announced pricing of a $6 million public offering of shares at $0.14 per share.

Why Ascent Solar Technologies Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

ALLR

EGOX

FAAS

FLGC

GNLN

Grindrod Shipping Holdings Ltd Ordinary Shares

GRIN

HUBC

LGVC

MDIA

RELI

SPCB

STIX

TCBP

XXII

ZCMD

NIVF

Shares of  Reliance Global Group, Inc.  (NASDAQ: RELI) fell sharply in today’s pre-market trading after reporting financial results for the year ended Dec 31, 2023.

Why Reliance Global Group Shares Are Trading Lower By Around 11%; Here Are 20 Stocks Moving Premarket

Nutex Health Inc

MDB Capital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDBH#NASDAQ">MDBH</a>) reported quarterly losses of $(0.83) per share. This is a 69.39 percent decrease over losses of $(0.49) per share from the same period last year.

Earnings

MDBH

MDB Capital Holdings Q3 EPS $(0.83) Down From $(0.49) YoY

WIIM

Alta Global Group shares are trading higher. The company announced it filed a request to withdraw its Form F-1 registration with the SEC.

Retail Sales

SONM

Sonim Technologies Announced It Just Unveiled The New XP Pro 5G Next Generation Ultra Rugged Smartphone Supporting Verizon's 5G Ultra Wideband

MATW

Matthews International shares are trading higher after the company reported better-than-expected Q4 EPS and sales.

MODD

Modular Medical shares are trading lower after the company announced a proposed public offering.

CETX

Cemtrex shares are trading lower after the company announced its board approved a 1-for-35 reverse stock split.

Buybacks

CBRE

CBRE Announces Expanded Stock Repurchase Authorization Of Up To $5B

Dividends

NGVC

Natural Grocers By Vitamin Cottage Increases Quarterly Dividend From $0.10 To $0.12

The company projects that it will generate:
<ul>
<li>greater than $2.1 billion of EBITDA and approximately $1.6 billion of cash from operations in a normalized macroeconomic environment before the benefit of circular investments, and</li>
<li>additional EBITDA of &gt;$500 million by 2029 through its circular initiatives:
<ul>
<li>&gt;$350 million of EBITDA from Kingsport, Tenn., and Longview, Texas, methanolysis projects, and</li>
<li>$150 million–$200 million of EBITDA from its cellulosic biopolymer platform</li>
</ul>
</li>
</ul>
The company also said it expects to generate an incremental $75 million–$100 million of EBITDA contribution in 2025 compared to 2024 from the Kingsport methanolysis facility.
Capital expenditures in 2025 are expected to be approximately $800 million. In 2026 and 2027, capital expenditures are expected to range between $800 million and $1 billion.

Guidance

Reported Earlier, Eastman Chemical Expects To Generate Significant EBITDA Growth Through Its Circular Economy Initiatives; Plans To Invest In Organic Growth For The Next Several Years

<a href="https://www.theinformation.com/articles/openai-considers-taking-on-google-with-browser" title="https://www.theinformation.com/articles/openai-considers-taking-on-google-with-browser">https://www.theinformation.com/articles/openai-considers-taking-on-google-with-browser</a>

GOOG

GOOGL

SSNLF

'OpenAI Considers Taking on Google With Browser' - The Information

Matthews International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MATW#NASDAQ">MATW</a>) reported quarterly earnings of $2.17 per share which beat the analyst consensus estimate of $2.00 by 8.5 percent. The company reported quarterly sales of $1.795 billion which beat the analyst consensus estimate of $1.789 billion by 0.31 percent.

Earnings Beats

Matthews International FY 2024 Adj. EPS $2.17 Beats $2.00 Estimate, Sales $1.795B Beat $1.789B Estimate

Potential first and only DHE autoinjector for tough-to-treat migraines and cluster headaches
Exenatide approval highlights Amneal's capabilities in developing GLP-1 injectables
Amneal Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRX#NASDAQ">AMRX</a>) ("Amneal" or the "Company"), a global pharmaceutical company, today announced the advancement of two key strategic initiatives. First, the Company has resubmitted to the U.S. Food and Drug Administration (FDA) its new drug application (NDA) for dihydroergotamine (DHE) prefilled syringe autoinjector for the acute treatment of migraine with or without aura and cluster headache in adults. Second, Amneal has received approval from the FDA for exenatide, which is the Company's first generic injectable glucagon-like peptide-1 (GLP-1) agonist and reflects its innovation capabilities in peptide development and drug-device combinations.

Biotech

General

AMRX

Amneal Resubmits DHE Autoinjector New Drug Application And Receives U.S. FDA Approval Of Exenatide, Its First Generic Injectable GLP-1 Agonist

Matthews International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MATW#NASDAQ">MATW</a>) reported quarterly earnings of $0.55 per share which beat the analyst consensus estimate of $0.38 by 44.74 percent. The company reported quarterly sales of $446.695 million which beat the analyst consensus estimate of $440.455 million by 1.42 percent. This is a 6.97 percent decrease over sales of $480.168 million the same period last year.

Matthews International Q4 2024 Adj. EPS $0.55 Beats $0.38 Estimate, Sales $446.695M Beat $440.455M Estimate

Offerings

SL Green Realty Announces $400M Proposed Offering Of Common Stock

A trademark filing from Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) has the cryptocurrency sector on high alert. President-elect Donald Trump's pro-crypto stance has already led to Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) hitting several new all-time highs <a href="https://www.benzinga.com/24/11/42102366/bitcoin-taps-95k-ethereum-dogecoin-flat-as-trumps-crypto-policy-takes-shape-top-analyst-describes-btcs-path-to-135k">since the 2024 election.</a>
What Happened: Fresh off of reports that Trump Media &amp; Technology Group was<a href="https://www.benzinga.com/general/social-media/24/11/42048594/trump-digs-deeper-into-cryptocurrency-bakkt-shares-soar-on-reported-interest-from-president-elects-media-company"> looking to acquire </a>cryptocurrency company Bakkt Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NYSE">BKKT</a>), a new trademark filing could further signal the media company's growing crypto aspirations.
Trademark attorney Josh Gerben <a href="https://x.com/JoshGerben/status/1859689670986408392">shared </a>a post about Trump Media Thursday, shown as T Media Tech LLC on the patent filing, which trademarks "TruthFi." The filing was made with the United States Patent and Trademark Office (USPTO) on Nov. 18, according to Gerben.
Gerben lists the following elements of the trademark <a href="https://tsdr.uspto.gov/#caseNumber=98859006&amp;caseSearchType=US_APPLICATION&amp;caseType=DEFAULT&amp;searchType=statusSearch">filing </a>for TruthFi:
<ul>
<li>Digital wallets</li>
<li>Analysis and compilation of data and statistics for financial research purposes</li>
<li>Payment processing of cryptocurrency and credit cards</li>
<li>Management of financial assets</li>
<li>Digital asset trading</li>
</ul>
Benzinga has contacted Trump Media for comment on the trademark filing.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent112124">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: Gerben <a href="https://www.nytimes.com/2024/11/21/business/trump-media-crypto-payment-service.html">told </a>the New York Times the trademark filing could be a way for Trump Media to reserve the desired name if it goes forward with plans for a crypto business.
While the trademark filing doesn't guarantee that Trump Media will enter the cryptocurrency sector, Gerben said there is a high chance of this.
"In my experience, most of the time if a client is going to file an application, there is something going on," Gerben told the Times.
The New York Times said Trump Media launching a cryptocurrency business could involve acquiring a company given its small employee count.
The Financial Times previously reported that Trump Media was in advanced talks to acquire Bakkt, a cryptocurrency company backed by Intercontinental Exchange (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>).
Bakkt&nbsp;<a href="https://www.benzinga.com/news/24/06/39234822/bakkt-holdings-explores-potential-sale-or-breakup-amid-crypto-sector-consolidation" target="_blank" rel="noreferrer noopener">said in June</a>&nbsp;it was exploring strategic alternatives that could include a sale or breakup of the company.
Trump does not have a role at Trump Media, but is <a href="https://www.benzinga.com/general/social-media/24/09/40943414/donald-trump-can-cash-out-his-trump-media-technology-stock-keep-company-control-heres-how-ma">the largest shareholder</a> of the company he co-founded, with around 53% of shares. Donald Trump Jr., his eldest son, is on the company&#8217;s board.
The president-elect<a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41096120/if-you-invested-1-000-in-bitcoin-when-donald-trump-said-he-wasnt-a-fan-heres-how-much-youd"> previously spoke ill</a> of Bitcoin and cryptocurrency before reversing course before the 2024 election, a move that won him potential votes from single-issue cryptocurrency voters.
An acquisition of Bakkt would push Trump&#8217;s media company and the president-elect deeper into the cryptocurrency sector, which comes after he promoted a crypto venture called&nbsp;World Liberty Financial&nbsp;with business partners.
A push into the cryptocurrency sector by Trump's media company and the appointment of new pro-crypto executives in his White House administration could prove to be a win-win for the president-elect.
DJT, BKKT Price Action: Trump Media shares gained 1.3% Thursday, closing at $30.49 versus a 52-week trading range of $22.55 to $79.38.
Bakkt shares were down 1.6% to $31.10 versus a 52-week trading range of $5.57 to $68.75. Bakkt stock is down 41% year-to-date, but higher in the last five days by more than 140%. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42071926/a-hedge-fund-hit-big-on-trumps-rumored-crypto-acquisition-and-is-up-1415-million">A Hedge Fund Hit Big On Trump&#8217;s Rumored Crypto Acquisition And Could Be Up $14.15 Million</a></li>
</ul>
Photo via Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Social Media

Politics

$BTC

Bakkt Holdings, Inc. Class A Common Stock

BKKT

Trump Media Trademark Filing For 'TruthFi' Hints At Potential Digital Wallets, Asset Trading

Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) reported its first-quarter results after Thursday's closing bell. Here's a look at the details from the report.&nbsp;
The Details: Intuit reported quarterly earnings of $2.50 per share, which beat the analyst consensus estimate of $2.35. Quarterly revenue came in at $3.28 billion which beat the consensus estimate of $3.14 billion and is an increase over sales of $2.98 billion from the same period last year.
<ul>
<li>Global Business Solutions Group revenue grew to $2.5 billion, up 9%. </li>
<li>Online Ecosystem revenue grew to $1.9 billion, up 20%.</li>
<li>Credit Karma revenue reached $524 million, up 29%.</li>
<li>Consumer Group revenue fell to $176 million, down 6%. </li>
<li>ProTax Group revenue dipped to $39 million, down 7%, as the company lapped the period a year ago that included the extended tax filing deadline for most California filers.</li>
</ul>
Read More: <a href="https://www.benzinga.com/general/social-media/24/11/42119493/rumble-eyes-buying-bitcoin-could-it-be-the-next-microstrategy">Rumble CEO Considers Bitcoin Investment, Engages Michael Saylor As Shares Rally</a>
&#8220;We&#8217;ve had a strong start to the year as we demonstrate the power of Intuit&#8217;s AI-driven expert platform strategy. By delivering &#8216;done-for-you&#8217; experiences, enabled by AI with access to AI-powered human experts, we continue to fuel the success of consumers and businesses,&#8221; said Sasan Goodarzi, Intuit&#8217;s CEO. 
&#8220;Our innovation and the proof points we&#8217;re observing continue to bolster our confidence in our strategy,&#8221; Goodarzi added. 
Outlook:&nbsp;Inuit reiterated its fiscal year guidance for earnings of between $19.16 and $19.36 per share, versus the $19.33 estimate, and revenue of between $18.16 billion and $18.347 billion, versus the $18.26 billion estimate. 
INTU Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Intuit shares are down 6.11% after-hours at $638.11 at the time of publication Thursday. 
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">Bitcoin Could Reach $1 Million By 2037, Economist Says: &#8216;Buy Of A Lifetime&#8217; Opportunity</a></li>
</ul>
Photo: Shutterstock

After-Hours Center

Tech

INTU

Intuit Shares Fall After Q1 Results, FY25 Guidance Below Estimates

<a href="https://www.globenewswire.com/Tracker?data=UazjiyA7FYuwHW9s153pGP2ZoDeKoZ432Puz3ZL5C_yNXYTQihrjr8-V__H60d-v9xPpUS5OIj7jIealf9fug75DYbfaBvJnKrOF0jJ_hgg=">Navitas Semiconductor</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) has announced that the company's revenue growth has been acknowledged for the third consecutive year, by Deloitte's <a href="https://www.globenewswire.com/Tracker?data=o5whUu19ezCIbnh7Jb6eVrNEUgDWp2aVmIYu90smtXHgfkO1fSxGg-7YVpW3Qwcj8aXSs3F_TJEYy9CEOKje0tyZJjroNCr4zE3h0teIGD6AtzdRGekHxUbZCiWM5YtOc6DCX--BTJTFNMzGAcCOgkD3HHJ34XlL3A6ApnAVuSP-JUeQH4LibRP-1aIVF4ggZ6dnGQYJqPS_LqKzGyN1Jg==">Technology Fast 500&#x2122;</a>. Navitas growth was driven by strong demand for its advanced, high-efficiency, wide-bandgap gallium nitride (GaN) and silicon carbide (SiC) power components, across a growing number of global markets and customers.
Now in its 30th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Based on percentage fiscal year revenue growth from 2020 to 2023, Navitas achieved 571% growth as GaN and SiC technology enabled efficient, sustainable applications and displaced legacy silicon chips.

NVTS

Navitas Semiconductor Announces That The Co's Revenue Growth Has Been Acknowledged By Deloitte's Technology Fast 500; Co Achieved 571% Growth As GaN And SiC Technology Enabled Efficient, Sustainable Applications And Displaced Legacy Silicon Chips

Gap Raises FY24 Gross Margin Growth From 200 Bps To 220 Bps; Raises Operating Income Margin From Mid-High 50% To Mid-High 60%; Lowers Effective Tax Rate From 28.0% To 26.5%.

Gap shares are trading higher after the company reported better-than-expected Q3 EPS and sales.

Dillard's Declares Record $25 Special Dividend And Regular $0.25 Quarterly Payout As Company Rewards Shareholders And Associates

Nutex Health regains Nasdaq compliance

Nutex Health GAAP EPS of -$0.07, revenue of $76.1M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Nutex Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/nutx-stock-quote/">NUTX</a>) just reported results for the second quarter of 2024.<ul><li>Nutex Health reported earnings per share of -7 cents. This was below the analyst estimate for EPS of -2 cents.</li><li>The company reported revenue of $76.08 million.</li><li>This was 9.16% better than the analyst estimate for revenue of $69.70 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/nutx-stock-earnings-nutex-health-for-q2-of-2024/">NUTX Stock Earnings: Nutex Health Misses EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

NUTX Stock Earnings: Nutex Health Misses EPS, Beats Revenue for Q2 2024

Nutex Health (NUTX) Q2 2024 Earnings Call Transcript

In a report released today, Bill Sutherland from Benchmark Co. maintained a Buy rating on Clinigence Holdings (NUTX – Research Report), with a pric...

Benchmark Co. Sticks to Its Buy Rating for Clinigence Holdings (NUTX)

Catalyst Watch: Nvidia's blockbuster earnings, CrowdStrike on the hot seat, and PCE inflation watch

Wall Street Breakfast: The Week Ahead

Nutex Health GAAP EPS of -$1.72, revenue of $78.79M

Nutex Health Inc. (NUTX) Q3 2024 Earnings Call Transcript

Benchmark Co. analyst Bill Sutherland maintained a Buy rating on Clinigence Holdings (NUTX – Research Report) today and set a price target of $60.0...

Benchmark Co. Reaffirms Their Buy Rating on Clinigence Holdings (NUTX)

ADSK

AFRM

AVGO

CHUY

CHWY

CLOV

CRWD

DELL

DIOD

DOMO

EXPE

FLUT

IBTA

LCID

LFUS

LGVN

LULU

MRVL

MSFT

NVDA

NVMI

OKTA

PSTG

RDDT

SANA

SMCI

SMXT

TCOM

TELA

UBXG

ULTA

VRCA

WEST

WKHS

Press Releases

Nutex Health Hospitals Prove Patient Satisfaction with Nine Awards and Honors Earned in Q2

NUTEX HEALTH REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE

NUTEX HEALTH SCHEDULES 2024 SECOND QUARTER FINANCIAL RESULTS RELEASE AND CONFERENCE CALL

NUTEX HEALTH REPORTS SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2024 FINANCIAL RESULTS

NUTEX HEALTH OPENS POST FALLS ER & HOSPITAL, ITS FIRST HOSPITAL IN IDAHO

NUTEX HEALTH HOSPITALS WIN MULTIPLE AWARDS IN THE 3rd QUARTER OF 2024

NUTEX HEALTH SCHEDULES 2024 THIRD QUARTER FINANCIAL RESULTS RELEASE AND CONFERENCE CALL

NUTEX HEALTH REPORTS THIRD QUARTER AND YEAR TO DATE SEPTEMBER 30, 2024 FINANCIAL RESULTS

NUTEX HEALTH OPENS MILWAUKEE ER & HOSPITAL, ITS SECOND LOCATION IN WISCONSIN

Comments

Nutex Health

Nutex Health (NUTX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga